Ambrosus, a blockchain-based ecosystem for the supply chain, has partnered with Trek Therapeutics, PBC to apply integrated sensors coupled with blockchain-based technology to pharmaceutical drug manufacturing in Trek’s clinical development program.
 
Ambrosus is building a publicly-verifiable, community-driven ecosystem to ensure the quality, safety, and origins of products, such as medicine and food, by combining high-tech sensors and blockchain, powered by smart contracts. As part of the collaboration, Ambrosus will conduct pilot projects with Trek to monitor the quality, safety and integrity of all stages of the pharmaceutical manufacturing process.
 
Trek Co-founder and chief executive officer, Dr. Ann Kwong said, “Currently the pharmaceutical manufacturing process is highly regulated by pharmaceutical manufacturers and by regulatory authorities in an extremely labor-intensive and expensive manner. We hope to partner with Ambrosus to create a continuous monitoring and tracking system that will be less labor intensive, less expensive, and more transparent to all parties with a stake in quality pharmaceutical manufacturing.
 
Our goal is to develop a system that is robust enough that Trek can submit data to support our manufacturing application for regulatory approval of our drugs from the FDA and EMA authorities.”
Ambrosus co-founder and chief executive officer, Angel Versetti said, “Following the successful implementation of the Ambrosus protocol in global food supply chains, we are delighted to now apply our blockchain protocol to help ensure the quality, safety and integrity of another vitally important product – pharmaceuticals.”